Traders should monitor for the filing of the resale registration statement and assess near-term downside risk from share overhang due to the large number of pre-funded warrants. The capital infusion supports clinical expansion but does not change near-term revenue prospects.
Price Chart
Executive Summary
Ovid Therapeutics announced a $60.0 million PIPE financing through the sale of common stock and pre-funded warrants, priced at $2.01 per share, with proceeds intended to expand development of its GABA-aminotransferase inhibitor OV329 into tuberous sclerosis complex and infantile spasms. The financing is led by Point72 and includes participation from several existing institutional investors.
Key Financial Metrics
Key Facts
- Ovid Therapeutics raised $60.0 million in a private placement (PIPE) financing.
- The offering includes 19,154,321 shares of common stock at $2.01 per share and pre-funded warrants for 10,701,710 shares at $2.009 per warrant.
- Pre-funded warrants have an exercise price of $0.001 and are immediately exercisable.
- Proceeds will support expansion of OV329 into tuberous sclerosis complex and infantile spasms, plus general R&D.
- Leerink Partners is lead placement agent; Oppenheimer & Co. and LifeSci Capital are co-agents.
- A registration rights agreement requires Ovid to file for resale registration with the SEC.
Financial Impact
$60.0 million gross proceeds, with potential for significant near-term dilution from warrant exercise
Risk Factors
- Significant dilution upon exercise of 10.7 million pre-funded warrants, even at minimal exercise price.
- No assurance that OV329 will succeed in new indications; clinical development risk remains high.
- Insider selling in the past 30 days may signal lack of confidence despite financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257973 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 10w ago | 144 | $2.89 | awaiting T+60 | — | $2.16 (−25.19%) |
Jul 8, 2026 15w ago | 8-K | $2.73 $2.49 | ▼ −8.79% | ▼ −11.10% | $2.16 (−20.81%) |
Jun 3, 2026 20w ago | 8-K | $2.39 $2.93 | ▲ +22.59% | ▲ +20.10% | $2.16 (−9.54%) |
May 12, 2026 24w ago | Press Release | $2.87 $2.65 | ▼ −7.67% | ▼ −12.05% | $2.16 (−24.67%) |
Apr 27, 2026 26w ago | EFFECT | $2.69 $2.38 | ▼ −11.52% | ▼ −16.30% | $2.16 (−19.63%) |
Apr 21, 2026 26w ago | S-3 | $2.66 $2.44 | ▼ −8.27% | ▼ −13.05% | $2.16 (−18.72%) |
Apr 20, 2026 27w ago | 8-K | $2.89 $2.49 | ▼ −13.84% | ▼ −20.62% | $2.16 (−25.19%) |
Mar 18, 2026 31w ago | 8-K | $2.30 $2.21 | ▼ −3.91% | ▼ −15.44% | $2.16 (−6.00%) |
Mar 18, 2026 31w ago | Press Release | $2.30 $2.21 | ▼ −3.91% | ▼ −15.44% | $2.16 (−6.00%) |
Mar 18, 2026 31w ago | Press Release | $2.30 $2.21 | ▼ −3.91% | ▼ −15.44% | $2.16 (−6.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers